UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2018

 

Creative Medical Technology Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   000-53500   87-0622284
(State or other jurisdiction of
incorporation) 		  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

2017 W Peoria Avenue, Phoenix, AZ 85029
(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (833) 336-7636

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events

 

On August 14, 2018, Creative Medical Technology Holdings, Inc., a Nevada corporation (the “ Company ”), issued a press release which included a shareholder update.

 

The press release, furnished as Exhibit 99.1 to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently available to the Company’s management and are current only as of the date made. Actual results could also differ materially from those anticipated as a result of a number of factors, including, but not limited to, those discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent reports filed by the Company with the Securities and Exchange Commission (the “ Commission ”). For those reasons, undue reliance should not be placed on any forward-looking statement. The Company assumes no duty or obligation to update or revise any forward-looking statement, although it may do so from time to time as management believes is warranted or as may be required by applicable securities law. Any such updates or revisions may be made by the registrant by filing reports with the Commission, through the issuance of press releases or by other methods of public disclosure.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated August 14, 2018

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Creative Medical Technology Holdings, Inc.
   
   
Date: August 15, 2018 By: /s/ Timothy Warbington
    Timothy Warbington, Chief Executive Officer

 

 

 

 

 

Exhibit 99.1

 

SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

 

Phoenix, AZ 8-14-18, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities.

 

Debt : Since our last 8k on debt reduction an additional $268,858.00 has been extinguished.

 

CaverStem™ : Domestic recruitment, vetting and training of physicians on the CaverStem™ program for the use of the patients own stem cells for the treatment of erectile dysfunction is continuing post AUA Conference in May 2018.

 

We wish to welcome some of the physicians in the CaverStem program;

 

Elias Said MD and Mark Bieri MD located in Las Cruces, NM. (caverstem-nm.com)

 

Victor Liu MD located in San Francisco, CA, (caverstem-sanfrancisco.com)

 

David Brown MD located in San Diego, CA, (caverstem-sandiego.com)

 

Barton Wachs MD located in Orange County, CA, (caverstem-oc.com)

 

Sheldon Freedman MD located in Las Vegas, CA, (caverstem-lasvegas.com)

 

Perinchery Narayan MD at North Florida Urology with offices in Orlando, Ocala, Gainsville, St. Augustine and Palatka, Fl. (caverstem-northflorida.com)

 

CaverStem™ International :

 

Implementation of our contract with Promo Med continues to move forward. We are also currently working with Dr. Alexander Buchmann with Alto Uro in Bern Switzerland to establish the CaverStem™ program in Switzerland, Germany and Austria. We are pleased with the opportunity to work with a highly regarded physician such as Dr. Buchmann to expand CaverStem™ in Europe.

 

CaverStem™ Clincal Trial : As per our contract with LA BioMed, the results will be made available 12 months after the last patient was enrolled. This will occur the end of August 2018. Once the data is received, analyzed and peer reviewed, the results will be jointly released by our company and LA BioMed.

 

American Urological Association Regional Conference : We will be exhibiting at this conference in Chicago September 5-9, 2018.

 

StemSpine™ : This patented technology for the use of stem cells for the treatment of degenerative disc disease represents the entry into a multi billion dollar market. The StemSpine™ model is the use of stem cells from bone marrow from the as with the CaverStem™ program.

 

AmnioStem™ : The AmnioStem™ program is meeting our expected development milestones.

 

Stroke, Medical Wasting, Radiation Toxicity and other patents : Our intellectual property portfolio is meeting our expected milestones and we intend to release information as our progress continues.

 

Summary : We have faced challenges but we continue to grow our programs strategically and efficiently. We are optimistic with the progress and fundamentals of our company.

 

We wish to thank our shareholders for their continued support.

 

 

 

 

About Creative Medical Technology Holdings

 

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our Caverstem™ procedure please go to www.caverstem.com.

 

Forward-Looking Statements

 

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

 

Contact:

Timothy Warbington

Chief Executive Officer

Tel: (480) 789-9939